Free Trial
→ Elon Musk’s $1 Quadrillion AI IPO (From Brownstone Research) (Ad)tc pixel
NASDAQ:IBRX

ImmunityBio Q4 2024 Earnings Report

ImmunityBio logo
$7.58 +0.15 (+2.02%)
Closing price 04:00 PM Eastern
Extended Trading
$7.72 +0.14 (+1.78%)
As of 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
ProfileEarnings HistoryForecast

ImmunityBio EPS Results

Actual EPS
-$0.15
Consensus EPS
-$0.26
Beat/Miss
Beat by +$0.11
One Year Ago EPS
N/A

ImmunityBio Revenue Results

Actual Revenue
$7.55 million
Expected Revenue
$8.74 million
Beat/Miss
Missed by -$1.19 million
YoY Revenue Growth
N/A

ImmunityBio Announcement Details

Quarter
Q4 2024
Date
3/3/2025
Time
Before Market Opens
Conference Call Date
Monday, March 3, 2025
Conference Call Time
7:00AM ET

Upcoming Earnings

ImmunityBio's Q1 2026 earnings is estimated for Monday, May 11, 2026, based on past reporting schedules, with a conference call scheduled on Friday, May 15, 2026 at 9:30 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Conference Call Resources

Powered by Quartr

Earnings Documents

ImmunityBio's Q4 2024 Press ReleasePress Release
(8-K)
ImmunityBio's Q4 2024 Annual reportAnnual report
(10-K)

ImmunityBio Earnings Headlines

ImmunityBio, Inc. Securities Fraud Class Action Result of FDA Warning and 21% Stock Decline - Investors may Contact Lewis Kahn, Esq, at Kahn Swick & Foti, LLC
 |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/05/06/3288452/6713/en/immunitybio-inc-securities-fraud-class-action-result-of-fda-warning-and-21-stock-decline-investors-may-contact-lewis-kahn-esq-at-kahn-swick-foti-llc.html
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in ImmunityBio, Inc. Of Class Action Lawsuit and Upcoming Deadlines – IBRX
May 5 at 5:31 PM  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/05/05/3288392/1087/en/investor-alert-pomerantz-law-firm-reminds-investors-with-losses-on-their-investment-in-immunitybio-inc-of-class-action-lawsuit-and-upcoming-deadlines-ibrx.html
You’re Being LIED To About The Iran War
The mainstream explanation for the Iran airstrikes may not be the full story. Addison Wiggin, Founder of Grey Swan Investment Fraternity, says there's a deeper motive behind the bombing campaign that most coverage is ignoring. If you're making investment decisions based on what you're hearing in the news, Wiggin argues you could be working with an incomplete picture.tc pixel
May 5 at 1:00 AM  |  Banyan Hill Publishing (Ad)
ImmunityBio, Inc. (IBRX) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit
May 5 at 3:40 PM  |  prnewswire.comhttps://www.prnewswire.com/news-releases/immunitybio-inc-ibrx-shareholders-who-lost-money-have-opportunity-to-lead-securities-fraud-lawsuit-302763101.html
IBRX SHAREHOLDER UPDATE: ImmunityBio (IBRX) Sued After FDA Flags Misleading Cancer Claims, Shares Plunge 21%, $2B Market Cap Lost -- Hagens Berman
May 5 at 1:53 PM  |  prnewswire.comhttps://www.prnewswire.com/news-releases/ibrx-shareholder-update-immunitybio-ibrx-sued-after-fda-flags-misleading-cancer-claims-shares-plunge-21-2b-market-cap-lost----hagens-berman-302763042.html
IBRX stock in spotlight: ImmunityBio to unveil fresh Anktiva and BCG data next week
May 5 at 10:20 AM  |  msn.comhttps://www.msn.com/en-us/money/other/ibrx-stock-in-spotlight-immunitybio-to-unveil-fresh-anktiva-and-bcg-data-next-week/ar-AA22qwvD
See More ImmunityBio Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like ImmunityBio? Sign up for Earnings360's daily newsletter to receive timely earnings updates on ImmunityBio and other key companies, straight to your email.

About ImmunityBio

ImmunityBio (NASDAQ:IBRX) is a clinical-stage biotechnology company specializing in the development of novel immunotherapies for cancer and infectious diseases. The company’s research platform centers on harnessing the power of the human immune system—through engineered T cells, natural killer (NK) cells, cytokine superagonists and viral-vectored vaccines—to target and eliminate diseased cells across a range of indications.

Among its lead assets is Anktiva (formerly known as N-803), an interleukin-15 superagonist designed to stimulate NK and T cell activity. Anktiva is being evaluated in combination with tumor-targeting monoclonal antibodies and immune checkpoint inhibitors for treatment of non–muscle-invasive bladder cancer as well as other solid tumors. In parallel, ImmunityBio is advancing novel T cell receptor (TCR) therapies and off-the-shelf NK cell products aimed at solid and hematologic malignancies.

Beyond oncology, the company has pursued viral-vectored vaccine candidates for infectious diseases, including a Phase 1 program for COVID-19. These efforts leverage a proprietary human adenovirus (hAd5) backbone intended to elicit robust cellular and humoral immune responses. ImmunityBio’s integrated approach combines cell engineering, cytokine biology and vaccine technology to build a diversified pipeline across multiple therapeutic areas.

Founded as NantKwest and rebranded to ImmunityBio in 2020, the company operates under the leadership of CEO Tarek Tantawi and was co-founded by biotech entrepreneur Dr. Patrick Soon-Shiong. Headquartered in Culver City, California, ImmunityBio conducts preclinical research and clinical trials in North America, Europe and Australia. The company maintains collaborations with academic institutions, government agencies and industry partners to accelerate development and regulatory filings for its immunotherapy candidates.

View ImmunityBio Profile
Earnings Tools